Publication date: Available online 23 October 2026 Source: Annals of the Rheumatic Diseases Author(s): Eisha Naveed, Alain Lescoat, Marco Matucci-Cerinic, Masataka Kuwana, Christopher P. Denton, Yannick Allanore, John D. Pauling, Francesco Del Galdo, Zsuzsanna McMahan, Jorg H.W. Distler, Janet Pope, Oliver Distler, Shervin Assassi, Robert Spiera, Lorinda Chung, Laura Cooney, Pei-Suen Tsou, John Varga, Dinesh Khanna
Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment. // Annals of the Rheumatic Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S0003496726005935?dgcid=rss_sd_all
Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment. Annals of the Rheumatic Diseases. https://www.sciencedirect.com/science/article/pii/S0003496726005935?dgcid=rss_sd_all
“Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment.” Annals of the Rheumatic Diseases.
@article{article88417,
title = {Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment},
journal = {Annals of the Rheumatic Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S0003496726005935?dgcid=rss_sd_all}
}
Objective Black patients with systemic sclerosis (scleroderma) have more severe disease than White patients. We investigated whether racial differences in therapeutic responses to mycophenolate mofetil (MMF) could explain this...